SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
|
|
|
þ
|
|
Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
For the quarterly period ended July 2, 2005
OR
|
|
|
o
|
|
Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
for the transition period from
to
.
Commission File Number: 01-14010
WATERS
CORPORATION
(Exact name of registrant as specified in the charter)
|
|
|
Delaware
|
|
13-3668640
|
(State or other jurisdiction of
|
|
(I.R.S. Employer Identification No.)
|
incorporation or organization)
|
|
|
34 Maple Street
Milford, Massachusetts 01757
(Address of principal executive offices)
Registrants telephone number, including area code: (508) 478-2000
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by
Section 13 or 15 (d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days
Yes
þ
No
o
Indicate by check mark whether the Registrant is an accelerated filer (as defined in Rule 12b-2 of
the Exchange Act).
Yes
þ
No
o
Number of
shares outstanding of the Registrants common stock as of
August 1, 2005: 115,005,472.
WATERS CORPORATION AND SUBSIDIARIES
QUARTERLY REPORT ON FORM 10-Q
INDEX
2
WATERS CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS, EXCEPT PER SHARE DATA)
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
July 2, 2005
|
|
December 31, 2004
|
ASSETS
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
615,234
|
|
|
$
|
539,077
|
|
Accounts receivable, less allowances for doubtful accounts and sales returns
of $8,207 and $7,100 at July 2, 2005 and December 31, 2004, respectively
|
|
|
228,245
|
|
|
|
271,731
|
|
Inventories
|
|
|
140,481
|
|
|
|
139,900
|
|
Other current assets
|
|
|
25,903
|
|
|
|
23,176
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
1,009,863
|
|
|
|
973,884
|
|
|
|
|
|
|
|
|
|
|
Property, plant and equipment, net of accumulated depreciation of
$152,132 and $151,462 at July 2, 2005 and December 31, 2004, respectively
|
|
|
139,243
|
|
|
|
135,908
|
|
Intangible assets, net
|
|
|
83,462
|
|
|
|
85,249
|
|
Goodwill
|
|
|
225,266
|
|
|
|
228,537
|
|
Other assets
|
|
|
34,560
|
|
|
|
36,848
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
1,492,394
|
|
|
$
|
1,460,426
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS EQUITY
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
Notes payable and debt
|
|
$
|
407,439
|
|
|
$
|
206,663
|
|
Accounts payable
|
|
|
39,264
|
|
|
|
46,180
|
|
Accrued employee compensation
|
|
|
16,395
|
|
|
|
33,709
|
|
Deferred revenue and customer advances
|
|
|
82,227
|
|
|
|
66,783
|
|
Accrued retirement plan contributions
|
|
|
14,151
|
|
|
|
10,655
|
|
Accrued income taxes
|
|
|
59,246
|
|
|
|
49,120
|
|
Accrued other taxes
|
|
|
8,289
|
|
|
|
12,547
|
|
Accrued warranty
|
|
|
10,985
|
|
|
|
10,565
|
|
Accrued litigation
|
|
|
3,036
|
|
|
|
4,652
|
|
Other current liabilities
|
|
|
41,549
|
|
|
|
52,116
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
682,581
|
|
|
|
492,990
|
|
Long-term liabilities:
|
|
|
|
|
|
|
|
|
Long-term debt
|
|
|
250,000
|
|
|
|
250,000
|
|
Long-term portion of retirement benefits
|
|
|
30,611
|
|
|
|
30,980
|
|
Other long-term liabilities
|
|
|
10,001
|
|
|
|
7,770
|
|
|
|
|
|
|
|
|
|
|
Total long-term liabilities
|
|
|
290,612
|
|
|
|
288,750
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
|
973,193
|
|
|
|
781,740
|
|
|
|
|
|
|
|
|
|
|
Commitments and contingencies (Notes 5, 6, 7, 8 and 11)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders equity:
|
|
|
|
|
|
|
|
|
Preferred stock, par value $0.01 per share, 4,000 shares authorized, none
issued at July 2, 2005 and December 31, 2004
|
|
|
|
|
|
|
|
|
Common stock, par value $0.01 per share, 400,000 shares authorized,
141,996 and 141,367 shares issued (including treasury shares) at
July 2, 2005 and December 31, 2004, respectively
|
|
|
1,420
|
|
|
|
1,414
|
|
Additional paid-in capital
|
|
|
381,224
|
|
|
|
366,224
|
|
Retained earnings
|
|
|
1,003,242
|
|
|
|
902,582
|
|
Treasury stock, at cost, 27,077 and 21,532 shares at July 2, 2005
and December 31, 2004, respectively
|
|
|
(903,778
|
)
|
|
|
(655,161
|
)
|
Deferred compensation
|
|
|
(332
|
)
|
|
|
(157
|
)
|
Accumulated other comprehensive income
|
|
|
37,425
|
|
|
|
63,784
|
|
|
|
|
|
|
|
|
|
|
Total stockholders equity
|
|
|
519,201
|
|
|
|
678,686
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and stockholders equity
|
|
$
|
1,492,394
|
|
|
$
|
1,460,426
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of the interim consolidated financial statements.
3
WATERS CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS, EXCEPT PER SHARE DATA)
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
July 2, 2005
|
|
July 3, 2004
|
Product sales
|
|
$
|
204,154
|
|
|
$
|
187,685
|
|
Service sales
|
|
|
80,476
|
|
|
|
72,803
|
|
|
|
|
|
|
|
|
|
|
Total net sales
|
|
|
284,630
|
|
|
|
260,488
|
|
|
|
|
|
|
|
|
|
|
Cost of product sales
|
|
|
77,396
|
|
|
|
70,580
|
|
Cost of service sales
|
|
|
39,670
|
|
|
|
35,600
|
|
|
|
|
|
|
|
|
|
|
Total cost of sales
|
|
|
117,066
|
|
|
|
106,180
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
167,564
|
|
|
|
154,308
|
|
|
|
|
|
|
|
|
|
|
Selling and administrative expenses
|
|
|
82,861
|
|
|
|
75,840
|
|
|
|
|
|
|
|
|
|
|
Research and development expenses
|
|
|
16,485
|
|
|
|
15,694
|
|
|
|
|
|
|
|
|
|
|
Purchased intangibles amortization
|
|
|
1,266
|
|
|
|
996
|
|
|
|
|
|
|
|
|
|
|
Litigation settlement (Note 7)
|
|
|
|
|
|
|
(17,124
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
|
66,952
|
|
|
|
78,902
|
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
(5,753
|
)
|
|
|
(1,891
|
)
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
5,290
|
|
|
|
2,886
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from operations before income taxes
|
|
|
66,489
|
|
|
|
79,897
|
|
|
|
|
|
|
|
|
|
|
Provision for income taxes
|
|
|
12,424
|
|
|
|
20,146
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
54,065
|
|
|
$
|
59,751
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per basic common share
|
|
$
|
0.47
|
|
|
$
|
0.50
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of basic common shares
|
|
|
116,092
|
|
|
|
118,691
|
|
|
|
|
|
|
|
|
|
|
Net income per diluted common share
|
|
$
|
0.46
|
|
|
$
|
0.49
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of diluted common shares and equivalents
|
|
|
117,722
|
|
|
|
122,820
|
|
The accompanying notes are an integral part of the interim consolidated financial statements.
4
WATERS CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS, EXCEPT PER SHARE DATA)
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended
|
|
|
July 2, 2005
|
|
July 3, 2004
|
Product sales
|
|
$
|
395,764
|
|
|
$
|
373,893
|
|
Service sales
|
|
|
157,171
|
|
|
|
141,681
|
|
|
|
|
|
|
|
|
|
|
Total net sales
|
|
|
552,935
|
|
|
|
515,574
|
|
|
|
|
|
|
|
|
|
|
Cost of product sales
|
|
|
150,941
|
|
|
|
143,139
|
|
Cost of service sales
|
|
|
77,926
|
|
|
|
70,515
|
|
|
|
|
|
|
|
|
|
|
Total cost of sales
|
|
|
228,867
|
|
|
|
213,654
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
324,068
|
|
|
|
301,920
|
|
|
|
|
|
|
|
|
|
|
Selling and administrative expenses
|
|
|
163,456
|
|
|
|
147,267
|
|
|
|
|
|
|
|
|
|
|
Research and development expenses
|
|
|
33,232
|
|
|
|
31,765
|
|
|
|
|
|
|
|
|
|
|
Purchased intangibles amortization
|
|
|
2,548
|
|
|
|
2,350
|
|
|
|
|
|
|
|
|
|
|
Litigation settlement and provisions, net (Note 7)
|
|
|
|
|
|
|
(9,277
|
)
|
|
|
|
|
|
|
|
|
|
Restructuring and other unusual charges, net (Note 8)
|
|
|
|
|
|
|
104
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
|
124,832
|
|
|
|
129,711
|
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
(9,912
|
)
|
|
|
(3,765
|
)
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
9,813
|
|
|
|
4,991
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from operations before income taxes
|
|
|
124,733
|
|
|
|
130,937
|
|
|
|
|
|
|
|
|
|
|
Provision for income taxes
|
|
|
24,073
|
|
|
|
30,341
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
100,660
|
|
|
$
|
100,596
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per basic common share
|
|
$
|
0.86
|
|
|
$
|
0.84
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of basic common shares
|
|
|
117,405
|
|
|
|
119,439
|
|
|
|
|
|
|
|
|
|
|
Net income per diluted common share
|
|
$
|
0.84
|
|
|
$
|
0.81
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of diluted common shares and equivalents
|
|
|
119,456
|
|
|
|
123,434
|
|
The accompanying notes are an integral part of the interim consolidated financial statements.
5
WATERS CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended
|
|
|
July 2, 2005
|
|
July 3, 2004
|
Cash flows from operating activities:
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
100,660
|
|
|
$
|
100,596
|
|
Adjustments to reconcile net income to net cash provided by
operating activities:
|
|
|
|
|
|
|
|
|
Provisions (recoveries) for doubtful accounts on accounts receivable
|
|
|
2,227
|
|
|
|
(44
|
)
|
Provisions on inventory
|
|
|
2,138
|
|
|
|
2,408
|
|
Deferred income taxes
|
|
|
(310
|
)
|
|
|
(59
|
)
|
Depreciation
|
|
|
11,814
|
|
|
|
10,562
|
|
Stock-based compensation
|
|
|
659
|
|
|
|
38
|
|
Amortization of intangibles
|
|
|
10,356
|
|
|
|
8,876
|
|
Tax benefit related to stock option exercises
|
|
|
2,990
|
|
|
|
16,268
|
|
|
|
|
|
|
|
|
|
|
Change in operating assets and liabilities, net of acquisitions and divestitures:
|
|
|
|
|
|
|
|
|
Decrease (increase) in accounts receivable
|
|
|
25,130
|
|
|
|
(7,991
|
)
|
Increase in inventories
|
|
|
(9,130
|
)
|
|
|
(6,544
|
)
|
Decrease (increase) in other current assets
|
|
|
4,908
|
|
|
|
(2,045
|
)
|
(Increase) decrease in other assets
|
|
|
(1,636
|
)
|
|
|
1,828
|
|
(Decrease) increase in accounts payable and other current liabilities
|
|
|
(7,189
|
)
|
|
|
3,337
|
|
Increase in deferred revenue and customer advances
|
|
|
18,886
|
|
|
|
11,883
|
|
Decrease in accrued litigation
|
|
|
(1,616
|
)
|
|
|
(15,310
|
)
|
Increase in other liabilities
|
|
|
3,167
|
|
|
|
4,340
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by operating activities
|
|
|
163,054
|
|
|
|
128,143
|
|
|
|
|
|
|
|
|
|
|
Cash flows from investing activities:
|
|
|
|
|
|
|
|
|
Additions to property, plant, equipment, software capitalization and
other intangibles
|
|
|
(26,651
|
)
|
|
|
(35,946
|
)
|
Business acquisitions, net of cash acquired
|
|
|
|
|
|
|
(41,467
|
)
|
|
|
|
|
|
|
|
|
|
Net cash used in investing activities
|
|
|
(26,651
|
)
|
|
|
(77,413
|
)
|
|
|
|
|
|
|
|
|
|
Cash flows from financing activities:
|
|
|
|
|
|
|
|
|
Net borrowings of bank debt
|
|
|
200,776
|
|
|
|
163,187
|
|
Proceeds from stock plans
|
|
|
11,182
|
|
|
|
21,577
|
|
Purchase of treasury shares
|
|
|
(248,617
|
)
|
|
|
(174,996
|
)
|
(Payments)
proceeds from debt swaps and other derivatives contracts
|
|
|
(8,218
|
)
|
|
|
1,047
|
|
|
|
|
|
|
|
|
|
|
Net cash (used in) provided by financing activities
|
|
|
(44,877
|
)
|
|
|
10,815
|
|
|
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash and cash equivalents
|
|
|
(15,369
|
)
|
|
|
1,653
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Increase in cash and cash equivalents
|
|
|
76,157
|
|
|
|
63,198
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at beginning of period
|
|
|
539,077
|
|
|
|
356,781
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of period
|
|
$
|
615,234
|
|
|
$
|
419,979
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of the interim consolidated financial statements.
6
WATERS CORPORATION AND SUBSIDIARIES
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(IN THOUSANDS, EXCEPT PER SHARE DATA)
1.
|
|
Basis of Presentation and Significant Accounting Policies
|
Waters Corporation (Waters or the Company), an analytical instrument manufacturer, designs,
manufactures, sells and services, through its Waters Division, high performance liquid
chromatography (HPLC), ultra performance liquid chromatography (UPLC) together with HPLC,
herein referred to as (LC) and mass spectrometry (MS) instrument systems and support products
including chromatography columns and other consumable products. These systems are complementary
products that can be integrated together and used along with other analytical instruments. LC is
a standard technique and is utilized in a broad range of industries to detect, identify, monitor
and measure the chemical, physical and biological composition of materials, and to purify a full
range of compounds. MS instruments are used in drug discovery and development, including
clinical trial testing, the analysis of proteins in disease processes (known as proteomics) and
environmental testing. LC is often combined with MS to create LC-MS instruments that include a
liquid phase sample introduction and separation system with mass spectrometric compound
identification and quantification. As a result of the acquisitions of Creon Lab Control AG
(Creon) in July 2003 and NuGenesis Technologies Corporation in February 2004, Waters Division
entered the laboratory informatics market (Laboratory Informatics). Laboratory Informatics
consists of laboratory-to-enterprise scale software systems for managing and storing scientific
information collected from a wide variety of instrument test methods. Through its TA Instruments
Division (TA), the Company designs, manufactures, sells and services thermal analysis and
rheometry instruments which are used in predicting the suitability of polymers and viscous
liquids for various industrial, consumer goods and health care products. The Company is also a
developer of and supplier of software based products which interface with the Companys
instruments and are typically purchased by customers as part of the instrument system.
The Companys interim fiscal quarter typically ends on the thirteenth Saturday of each
quarter. Since the Companys fiscal year-end is December 31, the first and fourth fiscal
quarters may not consist of thirteen complete weeks. The Companys second fiscal quarters for
2005 and 2004 ended on July 2, 2005 and July 3, 2004, respectively.
The accompanying unaudited interim consolidated financial statements have been prepared in
accordance with the instructions to Form 10-Q and do not include all the information and note
disclosures required by generally accepted accounting principles (GAAP) in the United States of
America. The consolidated financial statements include the accounts of the Company and its
subsidiaries. All material intercompany balances and transactions have been eliminated.
Certain amounts from prior years have been reclassified in the accompanying financial
statements in order to be consistent with the current years classifications.
The preparation of financial statements in conformity with GAAP requires management to make
estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii)
disclosure of contingent liabilities at the dates of the financial statements and (iii) the
reported amounts of revenues and expenses during the reporting periods. Actual results could
differ from those estimates.
It is managements opinion that the accompanying interim consolidated financial statements
reflect all adjustments (which are normal and recurring) necessary
for a fair statement of the
results for the interim periods. The interim consolidated financial statements should be read in
conjunction with the consolidated financial statements included in the Companys annual report on
Form 10-K filing with the Securities and Exchange Commission for the year ended December 31,
2004.
Stock-Based Compensation:
The Company has five stock-based compensation plans. The Company uses the intrinsic value method
of accounting prescribed by Accounting Principles Board Opinion (APB) 25, Accounting for Stock
Issued to Employees, and related interpretations, including Financial Interpretation (FIN) 44,
Accounting for Certain Transactions Involving Stock Compensation, for its plans. No
compensation expense has been recognized at the grant date for its fixed employee stock option
plans, except as noted below, or its employee stock purchase plan since all stock based
compensation awards are granted with the exercise price at the current fair value of the
Companys common stock as of the date of the award. The cost of time-based restricted stock
awards is initially recorded as deferred compensation and expensed over the respective vesting
period. Stock-based compensation expense recorded, related to restricted stock awards, except as
noted below, was immaterial for the three months and six months ended July 2, 2005 and July 3,
2004.
7
WATERS CORPORATION AND SUBSIDIARIES
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(IN THOUSANDS, EXCEPT PER SHARE DATA)
The following table illustrates the effect on net income and earnings per share (EPS) had
the Company applied the fair value recognition provisions of Statement of Financial Accounting
Standards (SFAS) 123, Accounting for Stock-Based Compensation, for the Companys five
stock-based compensation plans (in thousands, except per share data).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
|
|
|
Three Months
|
|
|
Six Months
|
|
|
Six Months
|
|
|
|
Ended
|
|
|
Ended
|
|
|
Ended
|
|
|
Ended
|
|
Compensation Expense - Fair Value Method
|
|
July 2, 2005
|
|
|
July 3, 2004
|
|
|
July 2, 2005
|
|
|
July 3, 2004
|
|
|
Net income, as reported
|
|
$
|
54,065
|
|
|
$
|
59,751
|
|
|
$
|
100,660
|
|
|
$
|
100,596
|
|
Deduct: total stock-based employee
compensation expense, net of related
tax effects
|
|
|
(5,938
|
)
|
|
|
(5,909
|
)
|
|
|
(11,815
|
)
|
|
|
(11,728
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Add: stock-based compensation
recognized in the consolidated
statements of operations, net of
related tax effects
|
|
|
447
|
|
|
|
15
|
|
|
|
483
|
|
|
|
30
|
|
|
|
|
|
|
Pro forma net income
|
|
$
|
48,574
|
|
|
$
|
53,857
|
|
|
$
|
89,328
|
|
|
$
|
88,898
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic as reported
|
|
$
|
0.47
|
|
|
$
|
0.50
|
|
|
$
|
0.86
|
|
|
$
|
0.84
|
|
Basic pro forma
|
|
$
|
0.42
|
|
|
$
|
0.45
|
|
|
$
|
0.76
|
|
|
$
|
0.74
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted as reported
|
|
$
|
0.46
|
|
|
$
|
0.49
|
|
|
$
|
0.84
|
|
|
$
|
0.81
|
|
Diluted pro forma
|
|
$
|
0.41
|
|
|
$
|
0.44
|
|
|
$
|
0.75
|
|
|
$
|
0.72
|
|
In December 2004, the Financial Accounting Standards Board (FASB) issued SFAS 123R
(revised 2004), Share-Based Payment, which requires the expensing of unvested stock options.
SFAS 123R was to be effective as of the third fiscal quarter of 2005; however, in April 2005, the
SEC amended the compliance date for public companies to the first annual period beginning after
June 15, 2005.
On December 31, 2004, the Company approved an amendment to accelerate the vesting of
approximately 238 thousand unvested stock options granted between December 2000 and February 2001
to certain employees of the Company. These options had an exercise price significantly greater
than the market value of the Companys stock at that time; hence, in accordance with APB 25 and
FIN 44, no compensation expense was recorded in the consolidated statements of operations. Each
stock option was scheduled to vest primarily in 2005, but became fully vested and exercisable on
December 31, 2004. The exercise price and number of shares underlying each affected stock option
were unchanged. The acceleration of these options was primarily done as a result of the issuance
of SFAS 123R which, under the modified prospective method, requires the expensing of unvested
stock options in the first annual reporting period that begins after June 15, 2005. As a result
of this acceleration, the Company recognized share-based compensation, net of related tax
effects, of $9.1 million in the fourth quarter of 2004 in the pro forma net income disclosure for
SFAS 123.
On May 4, 2005, the Company approved an amendment to accelerate the vesting of approximately
12 thousand unvested stock options and to extend the expiration date of approximately 36 thousand
stock options granted to a retiring non-employee director of the Company. The Company also
approved an amendment to accelerate the vesting of 2 thousand shares of the Companys restricted
common stock granted to the same director. Under APB 25 and FIN 44 these modifications resulted
in a charge which was recorded in selling and administrative expense in the consolidated
statements of operations of approximately $0.5 million for the three months ended July 2, 2005.
Product Warranty Costs:
The Company accrues estimated product warranty costs at the time of sale, which are included in
cost of sales in the consolidated statements of operations. While the Company engages in
extensive product quality programs and processes, including actively monitoring and evaluating
the quality of its component supplies, the Companys warranty obligation is affected by product
failure rates, material usage and service delivery costs incurred in correcting a product
failure. The amount of the accrued warranty liability is based on historical information such as
past experience, product failure rates, number of units repaired and estimated
costs of material and labor. The liability is reviewed for reasonableness at least quarterly.
8
WATERS CORPORATION AND SUBSIDIARIES
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(IN THOUSANDS, EXCEPT PER SHARE DATA)
The following is a rollforward of the Companys accrued warranty liability for the six
months ended July 2, 2005 and July 3, 2004:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at
|
|
|
Accruals for
|
|
|
Settlements
|
|
|
Balance at
|
|
|
|
Beginning of Period
|
|
|
Warranties
|
|
|
Made
|
|
|
End of Period
|
|
|
Accrued warranty liability
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
July 2, 2005
|
|
$
|
10,565
|
|
|
$
|
9,068
|
|
|
$
|
(8,648
|
)
|
|
$
|
10,985
|
|
July 3, 2004
|
|
$
|
11,051
|
|
|
$
|
9,101
|
|
|
$
|
(10,279
|
)
|
|
$
|
9,873
|
|
Stockholders Equity:
On October 25, 2004, the Companys Board of Directors authorized the Company to repurchase up to
an additional $500.0 million of its outstanding common shares over a two-year period. During the
three months ended July 2, 2005, the Company purchased 2.5 million shares of its common stock for
an aggregate of $100.1 million. As of July 2, 2005, the Company repurchased an aggregate of 6.8
million shares of its common stock under this program for an aggregate of $304.9 million.
On May 6, 2003, the Companys Board of Directors authorized the Company to repurchase up to
$400.0 million of its outstanding common shares over a two-year period. During the three months
ended July 3, 2004, the Company purchased 2.1 million shares of its common stock for $94.4
million, thus completing its $400.0 million stock buyback program. The total shares purchased
under this program were 11.8 million.
The Company believes that the share repurchase program benefits shareholders by increasing
earnings per share through reducing the number of shares outstanding and that the Company is
likely to have adequate financial flexibility to fund additional share repurchases given current
cash and debt levels.
2.
|
|
Inventories and Property, Plant and Equipment
|
Inventories
Inventories are classified as follows:
|
|
|
|
|
|
|
|
|
|
|
July 2, 2005
|
|
|
December 31, 2004
|
|
Raw materials
|
|
$
|
48,972
|
|
|
$
|
51,777
|
|
Work in progress
|
|
|
13,011
|
|
|
|
14,125
|
|
Finished goods
|
|
|
78,498
|
|
|
|
73,998
|
|
|
|
|
|
|
|
|
|
Total inventories
|
|
$
|
140,481
|
|
|
$
|
139,900
|
|
|
|
|
|
|
|
|
Property, Plant and Equipment
During the six months ended July 2, 2005, the Company retired and disposed of approximately $8.4
million of property, plant and equipment, most of which was fully depreciated and no longer in
use. Gains or losses on disposal were immaterial for the six months ended July 2, 2005.
NuGenesis:
In February 2004, the Company acquired all of the capital stock of NuGenesis Technologies
Corporation (NuGenesis), a company headquartered in Westborough, Massachusetts, for
approximately $42.9 million in cash. NuGenesis develops and markets the NuGenesis
®
Scientific Data Management System (SDMS).
The acquisition of NuGenesis was accounted for under the purchase method of accounting and
the results of operations of NuGenesis have been included in the consolidated results of the
Company from the acquisition date. The purchase price of the acquisition was allocated to
tangible and intangible assets and assumed liabilities based on their estimated fair values. The
Company has allocated $13.1 million of the purchase price to intangible assets comprised of
customer lists, trademarks and other purchased intangibles. The excess purchase price of $34.7
million after this allocation has been accounted for as goodwill.
9
WATERS CORPORATION AND SUBSIDIARIES
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(IN THOUSANDS, EXCEPT PER SHARE DATA)
The Company considered a number of factors to determine the purchase price allocation,
including engaging a third party valuation firm to independently appraise the fair value of
certain assets acquired. The following table presents the fair values of assets and liabilities
recorded in connection with the NuGenesis acquisition.
|
|
|
|
|
Cash
|
|
$
|
1,983
|
|
Accounts receivable
|
|
|
3,079
|
|
Inventory
|
|
|
121
|
|
Other current assets
|
|
|
194
|
|
Goodwill
|
|
|
34,741
|
|
Intangible assets
|
|
|
13,100
|
|
Fixed assets
|
|
|
722
|
|
Other assets
|
|
|
162
|
|
|
|
|
|
|
|
|
|
54,102
|
|
|
|
|
|
|
Accrued expenses and other current liabilities
|
|
|
6,817
|
|
Deferred tax liability
|
|
|
4,348
|
|
|
|
|
|
|
|
|
|
11,165
|
|
|
|
|
|
|
Cash consideration paid
|
|
$
|
42,937
|
|
|
|
|
|
|
In connection with the NuGenesis purchase price allocation, deferred tax liabilities were
established for the amortization of intangible assets for book purposes that were not deductible
for tax purposes in the U.S. In the third quarter of 2004, the Company transferred the NuGenesis
intangible assets to a foreign wholly-owned subsidiary where the Company expects to deduct the
amortization of the intangible assets for book and tax purposes. As a result, deferred tax
liabilities and goodwill were adjusted by $4.6 million during the year ended December 31, 2004.
The Company recorded approximately $1.1 million in purchase accounting liabilities relating
to the NuGenesis acquisition. Approximately $0.3 million had been utilized and $0.7 million had
been reversed as of December 31, 2004. The reversal was due to a change in managements plan to
continue use of a facility lease assumed as part of the acquisition until the end of its term in
June 2005. The remaining $0.1 million was utilized during the second quarter of 2005.
Rheometrics:
On January 15, 2003, the Company acquired the worldwide rheometry business of Rheometric
Scientific, Inc. (Rheometrics) for approximately $16.5 million in cash. This transaction was
accounted for under the purchase method of accounting and the results of operations of
Rheometrics have been included in the consolidated results of the Company from the acquisition
date. This business was integrated into the existing worldwide TA operations. The purchase
price of the acquisition was allocated to tangible and intangible assets and assumed liabilities
based on their estimated fair values.
The Company recorded approximately $4.1 million in purchase accounting liabilities relating
to the Rheometrics acquisition. The purchase accounting liabilities included $1.2 million for
severance costs for approximately 65 employees, all of whom were terminated as of December 31,
2004, and $0.9 million in facilities related costs for three facilities, all of which have been
closed as of December 31, 2004. Amounts accrued under purchase accounting related to the
Rheometrics acquisition were $0.3 million at July 2, 2005 and December 31, 2004.
Other
During the first quarter of 2004, the Company acquired various tangible and intangible assets of
certain Asian distributors totaling approximately $0.5 million.
The following represents the pro forma results of the ongoing operations for Waters and
NuGenesis as though the acquisition of NuGenesis had occurred at the beginning of the period
shown (in thousands, except per share data). The pro forma information, however, is not
necessarily indicative of the results that would have resulted had the acquisition occurred at
the beginning of the period presented, nor is it necessarily indicative of future results.
10
WATERS CORPORATION AND SUBSIDIARIES
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(IN THOUSANDS, EXCEPT PER SHARE DATA)
|
|
|
|
|
|
|
Six Months Ended
|
|
|
|
July 3, 2004
|
|
Net revenues
|
|
$
|
516,890
|
|
Net income
|
|
|
97,731
|
|
Income per basic common share
|
|
|
0.82
|
|
Income per diluted common share
|
|
|
0.79
|
|
4. Goodwill and Other Intangibles
The carrying amount of goodwill was $225.3 million and $228.5 million at July 2, 2005 and
December 31, 2004, respectively. The decrease is attributable to currency translation
adjustments of approximately $3.2 million.
The Companys intangible assets in the consolidated balance sheets are detailed as follows
(in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
July 2, 2005
|
|
|
December 31, 2004
|
|
|
|
Gross
|
|
|
|
|
|
|
Weighted -Average
|
|
|
Gross
|
|
|
|
|
|
|
Weighted-Average
|
|
|
|
Carrying
|
|
|
Accumulated
|
|
|
Amortization
|
|
|
Carrying
|
|
|
Accumulated
|
|
|
Amortization
|
|
|
|
Amount
|
|
|
Amortization
|
|
|
Period
|
|
|
Amount
|
|
|
Amortization
|
|
|
Period
|
|
|
|
|
|
Purchased intangibles
|
|
$
|
62,221
|
|
|
$
|
24,888
|
|
|
11 years
|
|
$
|
64,814
|
|
|
$
|
22,812
|
|
|
11 years
|
Capitalized software
|
|
|
75,544
|
|
|
|
41,823
|
|
|
3 years
|
|
|
66,186
|
|
|
|
35,384
|
|
|
3 years
|
Licenses
|
|
|
9,672
|
|
|
|
4,637
|
|
|
9 years
|
|
|
9,500
|
|
|
|
4,122
|
|
|
10 years
|
Patents and other
intangibles
|
|
|
10,772
|
|
|
|
3,399
|
|
|
8 years
|
|
|
9,829
|
|
|
|
2,762
|
|
|
8 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
158,209
|
|
|
$
|
74,747
|
|
|
7 years
|
|
$
|
150,329
|
|
|
$
|
65,080
|
|
|
7 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months ended July 2, 2005 and July 3, 2004, amortization expense for
intangible assets was $5.1 million and $4.5 million, respectively. For the six months ended July
2, 2005 and July 3, 2004, amortization expense for intangible assets was $10.4 million and $8.9
million, respectively. Amortization expense for intangible assets is estimated to be
approximately $20.7 million for each of the next five years. Foreign currency translation
decreased gross carrying amount and accumulated amortization for intangible assets by
approximately $2.7 million and $0.7 million, respectively, during the six months ended July 2,
2005.
In December 2004, the Company entered into a syndicated committed Credit Agreement (the Credit
Agreement) that provides for a $250.0 million term loan facility and a $450.0 million revolving
facility, which includes both a letter of credit and a swingline subfacility. At July 2, 2005
and December 31, 2004, the Company had aggregate borrowings under the Credit Agreement of $610.0
million and $440.0 million, respectively, and an amount available to borrow of $88.2 million and
$256.8 million, respectively, after outstanding letters of credit. At July 2, 2005 and December
31, 2004, the $250.0 million term loan was fully drawn and classified as long-term debt.
The Company, and its foreign subsidiaries, also had available short-term lines of credit,
totaling $122.1 million at July 2, 2005 and $95.7 million at December 31, 2004. At July 2, 2005
and December 31, 2004, related short-term borrowings were $47.4 million at a weighted average
interest rate of 3.26% and $16.7 million at a weighted average interest rate of 2.45%,
respectively.
Hedging Transactions
Hedges of Net Investments in Foreign Operations
During the second quarter of 2005, the Company hedged its net investment in Yen and Euro foreign
affiliates with cross-currency interest rate swaps, with notional values of $26.0 million and
$30.0 million, respectively. At July 2, 2005 and December 31, 2004, the notional amounts of
outstanding contracts were $30.0 million and $37.0 million, respectively.
11
WATERS CORPORATION AND SUBSIDIARIES
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(IN THOUSANDS, EXCEPT PER SHARE DATA)
During the second quarter of 2005, the Company hedged its net investment in British pound
foreign affiliates with range forward and forward foreign exchange contracts in British pounds.
Under the terms of the range forward agreements, the Company purchases an option below the
current spot rate to sell British pounds, and sells an option to its counterparties above the
current spot rate to buy British pounds, with option premiums that offset. As of July 2, 2005
and December 31, 2004, the Company had combined range forward and forward foreign exchange
contracts outstanding in British pounds with notional amounts of 75.0 million and 45.0 million
British pounds, respectively.
The Company has designated the forward exchange agreements described above as hedges of net
investments, and accordingly the changes in fair value associated with these forward exchange
agreements are recorded in accumulated other comprehensive income in the consolidated balance
sheets.
Other
The Company enters into forward foreign exchange contracts, principally to hedge the impact of
currency fluctuations on certain inter-company balances. Principal hedged currencies include the
Euro, Japanese Yen and British pound. The periods of these forward contracts typically range
from one to three months and have varying notional amounts which are intended to be consistent
with changes in inter-company balances. Gains and losses on these forward contracts are recorded
in selling and administrative expenses in the consolidated statements of operations. At July 2,
2005 and December 31, 2004, the Company held forward foreign exchange contracts with notional
amounts totaling approximately $71.9 million and $62.9 million, respectively.
The Companys effective tax rates for the three months ended July 2, 2005 and July 3, 2004 were
18.7% and 25.2%, respectively. The effective tax rate for the three months ended July 3, 2004
was impacted by the net tax effect of a litigation settlement. The effective tax rate, excluding
this item and corresponding tax effect, was 22.0% for the three months ended July 3, 2004. For
the quarter ended July 2, 2005, the Company lowered its effective tax rate from 20.0% to 19.3% on
a full year basis. This is attributable to the Companys quarterly assessment of projected full
year taxable income by jurisdiction. The decrease in effective tax rates for the three months
ended July 2, 2005 from July 3, 2004, excluding the previously described items, is primarily
attributable to the increase in income in international jurisdictions with lower effective tax
rates.
The Companys effective tax rates for the six months ended July 2, 2005 and July 3, 2004
were 19.3% and 23.2%, respectively. The effective tax rate for the six months ended July 3, 2004
was impacted by the net tax effect of certain litigation charges and settlements. The effective
tax rate, excluding these items and corresponding tax effects, was 22.0% for the six months ended
July 3, 2004. The decrease in effective tax rates for the six months ended July 2, 2005 from
July 3, 2004, excluding the previously described items, is primarily attributable to the increase
in income in international jurisdictions with lower effective tax rates.
In October 2004, the American Jobs Creation Act of 2004 (AJCA) was signed into law. The
AJCA contains a series of provisions, several of which are pertinent to the Company. The AJCA
creates a temporary incentive for U.S. multi-national corporations to repatriate accumulated
income abroad by providing an 85% dividends received deduction for certain dividends from
controlled foreign corporations. It has been the Companys practice to permanently reinvest all
foreign earnings into foreign operations. On July 12, 2005, the Board of Directors of the
Company approved the repatriation of $500.0 million as a qualified distribution in accordance
with the AJCA. The Company will use the repatriated cash to fund current and future operating
expenses within the parameters of IRS guidance. During the third quarter of 2005, the Company
will record a tax liability of approximately $22.0 million to $28.0 million for the federal,
state and foreign taxes related to such repatriation.
Applera Corporation:
On March 2, 2004, the Company and MDS, Inc., through its Applied Biosystems/MDS Sciex Instruments
partnership, and Applera Corporation Applied Biosystems entered into a settlement agreement
(the Applera Settlement Agreement) with respect to the various civil actions pending against
each of them, both in the United States and internationally. Stipulations of Dismissal or their
foreign equivalents (the Stipulations) with respect to the disposal of all such actions have
been entered in the applicable courts and tribunals in each of the United States, the United
Kingdom, Canada and Japan.
12
WATERS CORPORATION AND SUBSIDIARIES
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(IN THOUSANDS, EXCEPT PER SHARE DATA)
The Applera Settlement Agreement provides for the resolution of all patent infringement
claims in the United States made by certain of the parties against the other and of international
cases brought by MDS, Inc. and Applied Biosystems/MDS Sciex Instruments against the Company with
respect to alleged infringements of those parties patents at issue in the United Kingdom, Canada
and Japan.
In consideration of entering into the Applera Settlement Agreement and the Stipulations, the
Company and MDS, Inc. and Applied Biosystems/MDS Sciex Instruments have entered into royalty
paying license agreements, cross licensing the use of the technology described in the parties
respective patents at issue. In addition, the Company made a one-time payment to Applied
Biosystems/MDS Sciex Instruments of $18.1 million on March 11, 2004.
The accrued patent litigation expenses in the consolidated balance sheets as of July 2, 2005
and December 31, 2004 were zero and $0.1 million, respectively. There were no charges in the
consolidated statements of operations for the six months ended July 2, 2005 and July 3, 2004
related to this case.
Hewlett-Packard Company:
The Company filed suit in the United States against Hewlett-Packard Company and Hewlett-Packard
GmbH (collectively, HP), seeking a declaration that certain Company products sold under the
mark Alliance do not constitute an infringement of one or more patents owned by HP or its
foreign subsidiaries (the HP patents). The action in the United States was dismissed for lack
of controversy. Actions seeking revocation or nullification of foreign HP patents were filed by
the Company in Germany, France and England. A German patent tribunal found the HP German patent
to be valid. In Germany, France and England, HP and its successor, Agilent Technologies
Deutschland GmbH (Agilent), have brought an action alleging that certain features of the Alliance pump may
infringe the HP patents. In England, the Court of Appeal has found the HP patent valid and
infringed. The Companys petitions for leave to appeal to the House of Lords were denied. A
trial on damages was scheduled for November 2004. In
March 2004, Agilent brought a new action against the Company alleging that certain features of the Alliance pump
continue to infringe the HP patents. At a hearing held in the UK on June 8, 2004, the UK court
postponed the previously scheduled November 2004 damages trial until March 2005. Instead, the
court scheduled the trial in the new action for December 2004. In December 2004, following a
trial in the new action, the UK court ruled that the Company did not
infringe the HP patents. Agilent filed an appeal in that action, which was heard in July 2005, and the UK Appellate Court
upheld the lower Courts ruling of non-infringement. The damages trial scheduled for March 2005
has been postponed pending this appeal and rescheduled for December 2005. In France, the Paris
District Court has found the HP patent valid and infringed by the Alliance pump. The Company
appealed the French decision and on April 12, 2004 the French appeals court affirmed the Paris
District Courts finding of infringement. The Company has filed a further appeal in the case. In
the German case, a German court has found the patent infringed. The Company appealed the German
decision, and in December 2004 the German appeals court reversed the trial court and issued a
finding of non-infringement in favor of the Company. Agilent is
seeking an appeal in that action and in July 2005 brought a new
action against the Company alleging that certain features of the
Alliance pump continue to infringe the HP patents. The Company is
currently assessing the impact of this new action.
The Company recorded a provision of $7.8 million in the first quarter of 2004 for estimated
damages and fees to be incurred with respect to the ongoing litigation for the England and France
suits, excluding the effect of the recent suit filed in March 2004. This provision represents
managements best estimate of the probable and reasonably estimable loss related to this
litigation. No provision has been made for the Germany suits since the
Company believes that the loss contingencies are not probable. The accrued patent litigation expense in the consolidated balance sheets at
July 2, 2005 and December 31, 2004 were $3.0 million and $4.5 million, respectively, for the
England and France suits. The liability includes a provision of $0.8 million made in 2002. The
change in the liability since December 31, 2004 is attributable to payments of legal fees
directly associated with the cases.
8.
|
|
Restructuring and Other Unusual Charges, net
|
2004 Restructuring:
In January 2004, the Company initiated a restructuring effort to realign its personnel between
various support functions and field sales and service organizations around the world. As a
result, 70 employees were terminated, all of whom have left the Company. The provision of $2.1
million represents costs incurred, including severance costs, for the 70 people and other
directly related incremental costs of this realignment effort. The Companys 2004 restructuring
liability was zero at July 2, 2005 and December 31, 2004.
13
WATERS CORPORATION AND SUBSIDIARIES
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(IN THOUSANDS, EXCEPT PER SHARE DATA)
2002 Restructuring:
In July 2002, the Company took action to restructure and combine the Companys field sales,
service and distribution organizations of its Micromass and HPLC operations. In May 2003, the
Company took action to restructure and combine the Companys Micromass and HPLC manufacturing
operations. The objective of these integrations was to leverage the strengths of both divisions
and align and reduce operating expenses. The integration efforts impacted the U.S., Canada,
continental Europe and the United Kingdom. Approximately 55 employees were terminated, all of
whom have left the Company. In addition, the Company originally committed to closing four sales
and distribution facilities, two of which were closed as of December 31, 2004. During the three
months ended April 3, 2004, the Company reversed approximately $2.0 million in restructuring
accruals, primarily attributable to a change in plans with respect to two facilities previously
selected for closure and distributor contract settlements being less than previously estimated.
The Companys 2002 integration restructuring liability was zero at July 2, 2005 and December 31,
2004.
Basic and diluted earnings per share calculations are detailed as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended July 2, 2005
|
|
|
|
Income
|
|
|
Shares
|
|
|
Per Share
|
|
|
|
(Numerator)
|
|
|
(Denominator)
|
|
|
Amount
|
|
Net income per basic common share
|
|
$
|
54,065
|
|
|
|
116,092
|
|
|
$
|
0.47
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effect of dilutive securities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Options and restricted stock outstanding
|
|
|
|
|
|
|
1,616
|
|
|
|
|
|
Options exercised and cancellations
|
|
|
|
|
|
|
14
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per diluted common share
|
|
$
|
54,065
|
|
|
|
117,722
|
|
|
$
|
0.46
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended July 3, 2004
|
|
|
|
Income
|
|
|
Shares
|
|
|
Per Share
|
|
|
|
(Numerator)
|
|
|
(Denominator)
|
|
|
Amount
|
|
Net income per basic common share
|
|
$
|
59,751
|
|
|
|
118,691
|
|
|
$
|
0.50
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effect of dilutive securities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Options and restricted stock outstanding
|
|
|
|
|
|
|
3,828
|
|
|
|
|
|
Options exercised and cancellations
|
|
|
|
|
|
|
301
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per diluted common share
|
|
$
|
59,751
|
|
|
|
122,820
|
|
|
$
|
0.49
|
|
|
|
|
|
|
|
|
|
|
|
14
WATERS CORPORATION AND SUBSIDIARIES
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(IN THOUSANDS, EXCEPT PER SHARE DATA)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended July 2, 2005
|
|
|
|
Income
|
|
|
Shares
|
|
|
Per Share
|
|
|
|
(Numerator)
|
|
|
(Denominator)
|
|
|
Amount
|
|
Net income per basic common share
|
|
$
|
100,660
|
|
|
|
117,405
|
|
|
$
|
0.86
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effect of dilutive securities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Options and restricted stock outstanding
|
|
|
|
|
|
|
1,988
|
|
|
|
|
|
Options exercised and cancellations
|
|
|
|
|
|
|
63
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per diluted common share
|
|
$
|
100,660
|
|
|
|
119,456
|
|
|
$
|
0.84
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended July 3, 2004
|
|
|
|
Income
|
|
|
Shares
|
|
|
Per Share
|
|
|
|
(Numerator)
|
|
|
(Denominator)
|
|
|
Amount
|
|
Net income per basic common share
|
|
$
|
100,596
|
|
|
|
119,439
|
|
|
$
|
0.84
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effect of dilutive securities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Options and restricted stock outstanding
|
|
|
|
|
|
|
3,538
|
|
|
|
|
|
Options exercised and cancellations
|
|
|
|
|
|
|
457
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per diluted common share
|
|
$
|
100,596
|
|
|
|
123,434
|
|
|
$
|
0.81
|
|
|
|
|
|
|
|
|
|
|
|
For both the three months and six months ended July 2, 2005, the Company had 3.2 million
stock option securities that were antidilutive. For both the three months and six months ended
July 3, 2004, the Company had 1.4 million stock option securities that were antidilutive. These
securities were not included in the computation of diluted EPS. The effect of dilutive
securities was calculated using the treasury stock method.
Comprehensive income details follow (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
|
|
|
Three Months
|
|
|
Six Months
|
|
|
Six Months
|
|
|
|
Ended
|
|
|
Ended
|
|
|
Ended
|
|
|
Ended
|
|
|
|
July 2, 2005
|
|
|
July 3, 2004
|
|
|
July 2, 2005
|
|
|
July 3, 2004
|
|
Net income
|
|
$
|
54,065
|
|
|
$
|
59,751
|
|
|
$
|
100,660
|
|
|
$
|
100,596
|
|
Other comprehensive income (loss):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency translation adjustments
|
|
|
(21,152
|
)
|
|
|
(10,308
|
)
|
|
|
(33,967
|
)
|
|
|
(3,841
|
)
|
Net appreciation (depreciation) and realized gains
(losses) on derivative instruments
|
|
|
5,153
|
|
|
|
2,104
|
|
|
|
8,053
|
|
|
|
1,997
|
|
Unrealized gains (losses) on investment, net of tax
|
|
|
153
|
|
|
|
(607
|
)
|
|
|
(445
|
)
|
|
|
(187
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income
|
|
$
|
38,219
|
|
|
$
|
50,940
|
|
|
$
|
74,301
|
|
|
$
|
98,565
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15
WATERS CORPORATION AND SUBSIDIARIES
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(IN THOUSANDS, EXCEPT PER SHARE DATA)
The components of net periodic pension cost related to the U.S. Waters Retirement Plan are as
follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
|
|
|
Three Months
|
|
|
Six Months
|
|
|
Six Months
|
|
|
|
Ended
|
|
|
Ended
|
|
|
Ended
|
|
|
Ended
|
|
Components of Net Periodic Pension Cost
|
|
July 2, 2005
|
|
|
July 3, 2004
|
|
|
July 2, 2005
|
|
|
July 3, 2004
|
|
Service cost
|
|
$
|
1,571
|
|
|
$
|
1,383
|
|
|
$
|
3,142
|
|
|
$
|
2,766
|
|
Interest cost
|
|
|
961
|
|
|
|
847
|
|
|
|
1,922
|
|
|
|
1,694
|
|
Expected return on plan assets
|
|
|
(1,043
|
)
|
|
|
(743
|
)
|
|
|
(2,086
|
)
|
|
|
(1,486
|
)
|
Net amortization
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Prior service cost
|
|
|
(25
|
)
|
|
|
(25
|
)
|
|
|
(50
|
)
|
|
|
(50
|
)
|
Net actuarial loss
|
|
|
257
|
|
|
|
212
|
|
|
|
514
|
|
|
|
424
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net periodic pension cost
|
|
$
|
1,721
|
|
|
$
|
1,674
|
|
|
$
|
3,442
|
|
|
$
|
3,348
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months and six months ended July 2, 2005, the Company made no contributions to
the Waters Retirement Plan (the Plan). During fiscal year 2005, the Company expects to
contribute approximately $6.5 million to the Plan.
The Company sponsors various non-U.S. retirement plans. The components of net periodic
pension cost related to these plans are as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
|
|
|
Three Months
|
|
|
Six Months
|
|
|
Six Months
|
|
|
|
Ended
|
|
|
Ended
|
|
|
Ended
|
|
|
Ended
|
|
Components of Net Periodic Pension Cost
|
|
July 2, 2005
|
|
|
July 3, 2004
|
|
|
July 2, 2005
|
|
|
July 3, 2004
|
|
Service cost
|
|
$
|
310
|
|
|
$
|
264
|
|
|
$
|
620
|
|
|
$
|
528
|
|
Interest cost
|
|
|
189
|
|
|
|
164
|
|
|
|
378
|
|
|
|
328
|
|
Expected return on plan assets
|
|
|
(128
|
)
|
|
|
(108
|
)
|
|
|
(256
|
)
|
|
|
(216
|
)
|
Net amortization
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Prior service cost
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net actuarial loss
|
|
|
14
|
|
|
|
3
|
|
|
|
28
|
|
|
|
6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net periodic pension cost
|
|
$
|
385
|
|
|
$
|
323
|
|
|
$
|
770
|
|
|
$
|
646
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12.
|
|
Business Segment Information
|
The Company evaluated its business activities that are regularly reviewed by the Chief Executive
Officer for which discrete financial information is available. As a result of this evaluation,
the Company determined that it has two operating segments: Waters Division and TA Division.
Waters Division is in the business of designing, manufacturing, distributing and servicing
LC instruments, columns, other consumables and mass spectrometry instruments that can be
integrated and used along with other analytical instruments. Additionally, as a result of the
acquisitions of Creon Lab Control AG in July 2003 and NuGenesis Technologies Corporation in
February 2004, Waters Division entered the laboratory informatics market (Laboratory
Informatics), which consists of laboratory-to-enterprise scale software systems for managing and
storing scientific information collected from a wide variety of instrument test methods. TA
Division is in the business of designing, manufacturing, distributing and servicing thermal
analysis and rheometry instruments. The Companys two divisions are its operating segments, which
have similar economic characteristics, product processes, products and services, types and
classes of customers, methods of distribution, and regulatory environments. Because of these
similarities, the two segments have been aggregated into one reporting segment for financial
statement purposes. Please refer to the consolidated financial statements for financial
information regarding the one reportable segment of the Company.
16
WATERS CORPORATION AND SUBSIDIARIES
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(IN THOUSANDS, EXCEPT PER SHARE DATA)
13.
|
|
Recent Accounting Standards Changes and Developments
|
In May 2005, the FASB issued SFAS No. 154 Accounting Changes and Error Corrections, which
replaces APB Opinion No. 20 Accounting Changes, and FASB Statement No. 3 Reporting Accounting
Changes in Interim Financial Statements, and changes the requirements for the accounting for and
reporting of a change in accounting principle. This Statement requires retrospective application
to prior periods financial statements of changes in accounting principle, unless it is
impracticable to determine either the period-specific effects or the cumulative effect of the
change. This Statement shall be effective for accounting changes and corrections of errors made
in fiscal years beginning after December 15, 2005. Early adoption is permitted for accounting
changes and corrections of errors made in fiscal years beginning after the date this Statement is
issued. At the present time, the Company does not believe that adoption of SFAS 154 will have a
material effect on its financial position, results of operations or cash flows.
In March 2005, the FASB issued FASB Interpretation No. 47 Accounting for Conditional Asset
Retirement Obligations, which is an interpretation of FASB Statement No. 143, Accounting for
Asset Retirement Obligations. The interpretation requires a liability for the fair value of a
conditional asset retirement obligation be recognized if the fair value of the liability can be
reasonably estimated. The interpretation is effective for years ending after December 15, 2005.
The interpretation is not expected to have a material impact on the Companys results of
operations or financial position.
In December 2004, the FASB issued SFAS No. 123(R) Share-Based Payments which amends SFAS
No. 123 Accounting for Stock-Based Compensation. This standard requires that all share-based
payments to employees, including grants of employee stock options, be recognized in the statement
of operations based on their fair values. The standard was originally to be effective for public
companies for interim periods beginning after June 15, 2005; however, in April 2005, the SEC
amended the compliance date for public companies to the first annual period beginning after June
15, 2005. The final standard allows alternative methods for determining fair value. At the
present time, the Company has not determined which valuation method it will use. The adoption of
SFAS No. 123(R) will have a material impact on the Companys results of operations. Future
results will be impacted by the number and value of additional equity awards as well as the value
of existing unvested equity awards.
In April 2005, the SEC issued Staff Accounting Bulletin (SAB) 107 Share-Based Payments
which expresses the SEC Staffs views regarding the application of SFAS No. 123(R). As noted
above, the adoption of SFAS No. 123(R), as applied using standards set forth in SAB 107, will
have a material impact on the Companys results of operations and financial position.
In December 2004, the FASB issued SFAS No. 153 Exchanges of Nonmonetary Assets which
amends Accounting Principles Board Opinion No. 29. This standard requires that exchanges of
nonmonetary assets be measured based on the fair value of the assets exchanged. This standard is
effective for nonmonetary asset exchanges occurring in fiscal periods beginning after June 15,
2005 and should be applied prospectively. At the present time, the Company does not believe that
adoption of SFAS 153 will have a material effect on its financial position, results of operations
or cash flows.
In November 2004, the FASB issued SFAS No. 151 Inventory Costs which amends Accounting
Research Bulletin No. 43 Chapter 4. This standard clarifies that abnormal amounts of idle
facility expense, freight, handling costs, and wasted materials (spoilage) should be recognized
as current period charges and requires the allocation of fixed production overheads to inventory
based on the normal capacity of the production facilities. This standard is effective for
inventory costs incurred during fiscal years beginning after June 15, 2005. At the present time,
the Company is evaluating SFAS 151 but does not believe that it will have a material effect on
its financial position, results of operations or cash flows.
17
|
|
|
Item 2.
|
|
MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
|
Beginning in 2005, the Waters Division has included single quadrupole instruments within its
reported mass spectrometry (MS) instrument system revenues. These had previously been categorized
as high performance liquid chromatography (HPLC) instrument systems. In addition, service
revenues for liquid chromatography (LC) and MS have been consolidated into a single service
revenue classification. These changes were made to reflect current business reporting subsequent to
the consolidation of the Waters Divisions LC and MS organizations. All product line and service
sales and sales growth percentages reported for the periods herein for Waters Division reflect the
new classifications as described above. The sales amounts that were reclassified between LC and MS
generally offset each other such that the relative proportions of sales classified as LC and MS
remained unchanged.
Business and Financial Overview:
Sales grew 9% for the three month period ended July 2, 2005 (the 2005 Quarter) over the three
month period ended July 3, 2004 (the 2004 Quarter). Sales grew 7% for the six month period ended
July 2, 2005 (the 2005 Period) over the six month period ended July 3, 2004 (the 2004 Period).
Currency translation effect accounted for approximately 1% of that sales growth for both the 2005
Quarter and 2005 Period.
During the first quarter of 2005, the Company experienced weakness in its European business
predominantly as a result of the delayed release of capital budgets by the Companys large
pharmaceutical customers. During the 2005 Quarter, the Companys European business strengthened as
certain delayed orders for the Companys products were released. The Company believes that
business in Europe is likely to continue to improve and that Europe is likely to finish the year
with positive sales growth. Outside of Europe, the Companys results were generally in-line with
managements expectations. Business growth was strongest in India, North America and Latin
America. While pharmaceutical sales grew during the 2005 Quarter, management believes that many
large pharmaceutical accounts are continuing to delay the release of capital budgets until the
second half of 2005.
Sales to industrial customers grew 4% in the 2005 Quarter and 7% in the 2005 Period. The TA
Instruments Division (TA), a business with a heavy industrial focus, delivered sales growth of 6%
for the 2005 Quarter and sales growth of 11% in the 2005 Period. Management anticipates that this
positive trend in industrial spending is likely to continue throughout the year.
With respect to the Waters Division, sales of LC, including HPLC and Ultra Performance Liquid
Chromatography (UPLC), grew 10% in the 2005 Quarter, primarily due to higher ACQUITY UPLC
shipments and strong service and LC consumables growth.
The Quattro Premier XE was one of the new MS products that the Company introduced at the
American Society of Mass Spectrometry (ASMS) conference in June 2005 and it began shipping in the
2005 Quarter. This new instrument is the highest performance tandem quadrupole system the Company
has designed. In the Q-Tof product line, the Company began shipping its new Protein Expression
system in the 2005 Quarter. Shipments of these new products were offset by declines in sales of
magnetic sector and MALDI Tof devices, resulting in MS sales growth of 5% for the 2005 Quarter.
Sales of Laboratory Informatics products, a business that is heavily influenced by
pharmaceutical spending, decreased by approximately $1.1 million in the 2005 Quarter compared to
the 2004 Quarter. Sales of these products continue to be below managements expectations.
However, the Company believes there is a viable market for these products and continues to pursue
growth opportunities in this business.
Operating income was $67.0 million in the 2005 Quarter, a decrease of $11.9 million from $78.9
million in the 2004 Quarter. The 2004 Quarter included a $17.1 million gain from a judgment
related to patent litigation with Perkin-Elmer Corporation. The net increase in operating income
of $5.2 million, excluding that gain, is primarily a result of the increase in sales and gross
profit, offset somewhat by higher selling and administrative expenses.
Operating income was $124.8 million in the 2005 Period, a decrease of $4.9 million from $129.7
million in the 2004 Period. The 2004 Period included a $17.1 million gain from a judgment related
to patent litigation with Perkin-Elmer Corporation and a litigation provision of $7.8 million
related to ongoing patent litigation with Hewlett-Packard Corporation. The net increase in
operating income of $4.4 million, excluding the litigation gain and provision, is primarily a
result of the increase in sales and gross profit, offset somewhat by higher selling and
administrative expenses.
Operating cash flows for the 2005 Period increased to $163.1 million from $128.1 million in
the 2004 Period. The increase is primarily due to the decrease in accounts receivable, a reduction
in the change in accrued litigation and an increase in deferred revenue. Capital expenditures
related to property, plant, equipment, software capitalization and other intangibles in the 2005
Period were $26.7 million compared to $35.9 million in the 2004 Period. The decrease in capital
expenditures in the 2005 Period is attributable to a purchase of a building in the 2004 Period.
18
The Company continues to evaluate the acquisition of businesses, product lines and
technologies to augment the Waters and TA operating divisions. Currently, however, management
expects to continue to apply the Companys strong cash generation to repurchasing shares of
Company stock through the $500.0 million program authorized by the Companys Board of Directors
in October 2004. During the 2005 Quarter, the Company purchased 2.5 million shares of its
common stock for an aggregate of $100.1 million. As of July 2, 2005, the Company had repurchased
an aggregate of 6.8 million shares of its common stock under this program for an aggregate of
$304.9 million. The Company believes that the share repurchase program benefits shareholders by
increasing earnings per share through reducing the number of shares outstanding and that the
Company is likely to have adequate financial flexibility to fund additional share repurchases
given current cash and debt levels.
Results of Operations:
Sales:
Sales for the 2005 Quarter and the 2005 Period were $284.6 million and $552.9 million,
respectively, compared to $260.5 million for the 2004 Quarter and $515.6 million for the 2004
Period, an increase of 9% for the 2005 Quarter and 7% for the 2005 Period. Currency translation
accounted for approximately 1% of that sales growth in both the 2005 Quarter and 2005 Period
primarily due to the strengthening of the Euro, British pound, Japanese Yen and Canadian dollar.
Product sales were $204.2 million and $395.8 million in the 2005 Quarter and 2005 Period,
respectively, compared to $187.7 million and $373.9 million in the 2004 Quarter and 2004 Period,
respectively, an increase of 9% for the 2005 Quarter and 6% for the 2005 Period. The increase in
product sales, aside from the effect of foreign currency translation, is primarily due to the
continued strength of the HPLC, MS and TA sales growth in the 2005 Quarter and 2005 Period.
Service sales were $80.5 million and $157.2 million in the 2005 Quarter and 2005 Period,
respectively, compared to $72.8 million and $141.7 million in the 2004 Quarter and 2004 Period,
respectively, an increase of 11% for both the 2005 Quarter and the 2005 Period. The increase,
aside from the effect of foreign currency translation, is primarily attributable to growth in the
Companys installed base of instruments and sales of service contracts.
The following commentary discusses the Companys sales performance by product line excluding
the effects of currency translation.
Within the Waters Division, LC sales grew approximately 10% in the 2005 Quarter and 6% in
the 2005 Period. Chemistry grew approximately 11% in the 2005 Quarter and 8% in the 2005 Period.
Service grew 11% in the 2005 Quarter and 9% in the 2005 Period due to increased sales of service
plans to the higher installed base of customers. LC instrument sales grew 10% in the 2005
Quarter compared with the 2004 Quarter and 3% in the 2005 Period. The increase in instrument
sales during the 2005 Quarter is primarily attributable to higher sales to pharmaceutical and
life science customers and higher sales of ACQUITY UPLC. Geographically, LC sales in the U.S.,
Europe, Asia and Japan strengthened approximately 6%, 11%, 11% and 8%, respectively, in the 2005
Quarter and 4%, 4%, 4% and 6%, respectively, in the 2005 Period.
Within the Waters Division, MS sales grew approximately 5% in the 2005 Quarter and the 2005
Period. Sales in the U.S. and Europe grew 29% and 4%, respectively, in the 2005 Quarter, while
sales in Asia and Japan declined by 25% and 15%, respectively. Sales in the U.S. grew 21% in the
2005 Period, while sales in Europe, Asia and Japan declined by 1%, 9%, and 1%, respectively.
Growth in the U.S. and Europe during the 2005 Quarter is largely due to sales growth of the
tandem quadrupole and Q-Tof systems. Offsetting this growth in the quarter were declines in
magnetic sector instrument revenues.
Within the Waters Division, sales of Laboratory Informatics products were $4.3 million in
the 2005 Quarter and $8.7 million in the 2005 Period, compared to $5.4 million in the 2004
Quarter and $10.3 million in the 2004 Period.
Within the TA Instruments Division, sales continued to be strong with sales growth of 5% for
the 2005 Quarter and 10% for the 2005 Period. TA product and service sales grew 3% and 12%,
respectively, in the 2005 Quarter and 8% and 16%, respectively, in the 2005 Period.
Geographically, growth in the TA business for the 2005 Quarter was predominantly in Asia and
Europe, with increased spending by core industrial chemical and pharmaceutical companies. The
Company established a direct operation in China in the third quarter of 2004 which augmented
Asias growth in the 2005 Quarter and the 2005 Period.
Gross Profit:
Gross profit for the 2005 Quarter and 2005 Period was $167.6 million and $324.1 million,
respectively, compared to $154.3 million and $301.9 million for the 2004 Quarter and 2004 Period,
respectively, an increase of 9% for the quarter and 7% for the period, respectively. Gross
profit as a percentage of sales decreased to 58.9% in the 2005 Quarter from 59.2% in the 2004
Quarter. The decline in gross profit margins in the 2005 Quarter is due to the change in sales
mix and the impact of a planned reduction in inventory levels. Gross profit as a percentage of
sales for both the 2005 and 2004 Periods was 58.6%.
19
Selling and Administrative Expenses:
Selling and administrative expenses for the 2005 Quarter and 2005 Period were $82.9 million and
$163.5 million, respectively, compared to $75.8 million for the 2004 Quarter and $147.3 million for
the 2004 Period. Selling and administrative expense as a percentage of sales for both the 2005 and
2004 Quarters was 29.1%. The $7.1 million or 9% increase in total selling and administrative
expenses for the 2005 Quarter is primarily attributable to an increase of approximately $1.9
million as a result of currency translation and an increase attributable to annual merit increases
effective in April of both years across most divisions, other headcount additions and related
fringe benefits and indirect costs of $4.6 million. As a percentage of sales, selling and
administrative expenses increased to 29.6% for the 2005 Period compared to 28.6% in the 2004
Period. The $16.2 million or 11% increase in total selling and administrative expenses for the
2005 Period is attributable primarily to the following: an increase of approximately $3.9 million
as a result of currency translation, an increase of approximately $1.7 million related to
Sarbanes-Oxley compliance expenses; an increase attributable to annual merit increases effective in
April of both years across most divisions, other headcount additions and related fringe benefits
and indirect costs of $8.7 million; an increase in travel expenses of $3.3 million and an increase
in expenses associated with a new building in Milford, Massachusetts acquired in the prior year.
The impact of these increases was offset by lower management incentive compensation expense.
Management believes that selling and administrative expenses will grow at, or slightly above, the
rate of sales growth for the full year.
Research and Development Expenses:
Research and development expenses were $16.5 million for the 2005 Quarter and $33.2 million for
the 2005 Period compared to $15.7 million for the 2004 Quarter and $31.8 million for the 2004
Period, an increase of 5% for the 2005 Quarter and the 2005 Period. Research and development
expenses increased $0.8 million for the 2005 Quarter and $1.4 million for the 2005 Period due
primarily to the merit increases effective in April of both years across most divisions, other
headcount additions and related fringe benefits and indirect costs, and currency translation.
Litigation Provisions:
The Company recorded the benefit of a litigation judgment in the 2004 Quarter in the amount of
$17.1 million and a provision of $7.8 million in the first quarter of 2004. The judgment benefit
received in the 2004 Quarter is related to the conclusion of the Companys litigation with
Perkin-Elmer Corporation. The provision in the 2004 Period is related to the ongoing patent
infringement litigation with Hewlett-Packard Corporation. There were no charges incurred in the
2005 Quarter and 2005 Period related to these cases.
Interest Expense:
Interest expense was $5.8 million for the 2005 Quarter and $9.9 million for the 2005 Period,
compared to $1.9 million for the 2004 Quarter and $3.8 million for the 2004 Period. The increase of $3.9
million for the 2005 Quarter and $6.1 million for the 2005 Period is due primarily to interest
expense on additional borrowings against the Companys credit facilities to fund the stock
repurchase program.
Interest Income:
Interest income was $5.3 million for the 2005 Quarter and $9.8 million for the 2005 Period,
compared to $2.9 million for the 2004 Quarter and $5.0 million for the 2004 Period. The increase in
interest income for the 2005 Quarter and the 2005 Period is primarily attributable to increases in
the Companys cash balances.
Provision for Income Taxes:
The Companys effective tax rates for the three months ended July 2, 2005 and July 3, 2004 were
18.7% and 25.2%, respectively. The effective tax rate for the three months ended July 3, 2004 was
impacted by the net tax effect of a litigation settlement. The effective tax rate, excluding this
item and corresponding tax effect, was 22.0% for the three months ended July 3, 2004. For the
quarter ended July 2, 2005, the Company lowered its effective tax rate from 20.0% to 19.3% on a
full year basis. This is attributable to the Companys quarterly assessment of projected full year
taxable income by jurisdiction. The decrease in effective tax rates for the three months ended
July 2, 2005 from July 3, 2004, excluding the previously described items, is primarily attributable
to the increase in income in international jurisdictions with lower effective tax rates.
The Companys effective tax rates for the six months ended July 2, 2005 and July 3, 2004 were
19.3% and 23.2%, respectively. The effective tax rate for the six months ended July 3, 2004 was
impacted by the net tax effect of certain litigation charges and settlements. The effective tax
rate, excluding these items and corresponding tax effects, was 22.0% for the six months ended July
3, 2004. The decrease in effective tax rates for the six months ended July 2, 2005 from July 3,
2004, excluding the previously described items, is primarily attributable to the increase in income
in international jurisdictions with lower effective tax rates.
20
In October 2004, the American Jobs Creation Act of 2004 (AJCA) was signed into law. The
AJCA contains a series of provisions, several of which are pertinent to the Company. The AJCA
creates a temporary incentive for U.S. multi-national corporations to repatriate accumulated
income abroad by providing an 85% dividends received deduction for certain dividends from
controlled foreign corporations. It has been the Companys practice to permanently reinvest all
foreign earnings into foreign operations. On July 12, 2005, the Board of Directors of the
Company approved the repatriation of $500.0 million as a qualified distribution in accordance
with the AJCA. The Company will use the repatriated cash to fund current and future operating
expenses within the parameters of IRS guidance. During the third quarter of 2005, the Company
will record a tax liability of approximately $22.0 million to $28.0 million for the federal,
state and foreign taxes related to such repatriation. It is expected that a majority of this tax
liability will be paid during the fourth quarter of 2005 and the first quarter of 2006.
Impact of New Accounting Pronouncements:
In December 2004, the FASB issued SFAS No. 123(R) Share-Based Payments (SFAS 123R) which amends
SFAS No. 123 Accounting for Stock-Based Compensation. This standard requires that all
share-based payments to employees, including grants of employee stock options, be recognized in the
statement of operations based on their fair values. This charge will be allocated to line items
within the statement of operations based on underlying employee service. The Company will begin
recognizing these charges in fiscal year 2006. The final standard allows alternative methods for
determining fair value. The Company is considering alternative equity compensation structures as
well as valuation methods. The adoption of SFAS 123R will have a material impact on the Companys
results of operations in various line items within the statements of operations. Due to the
alternatives being considered, management is unable to quantify the future impact on results of
operations.
Liquidity and Capital Resources
Condensed Consolidated Statements of Cash Flows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended
|
|
|
July 2, 2005
|
|
July 3, 2004
|
Net income
|
|
$
|
100,660
|
|
|
$
|
100,596
|
|
Depreciation and amortization
|
|
|
22,170
|
|
|
|
19,438
|
|
Tax benefit related to stock option exercises
|
|
|
2,990
|
|
|
|
16,268
|
|
Change in accounts receivable
|
|
|
25,130
|
|
|
|
(7,991
|
)
|
Change in inventories
|
|
|
(9,130
|
)
|
|
|
(6,544
|
)
|
Change in accounts payable and other current liabilities
|
|
|
(7,189
|
)
|
|
|
3,337
|
|
Change in deferred revenue and customer advances
|
|
|
18,886
|
|
|
|
11,883
|
|
Change in accrued litigation
|
|
|
(1,616
|
)
|
|
|
(15,310
|
)
|
Other changes in operating activities
|
|
|
11,153
|
|
|
|
6,466
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by operating activities
|
|
|
163,054
|
|
|
|
128,143
|
|
|
|
|
|
|
|
|
|
|
Net cash used in investing activities
|
|
|
(26,651
|
)
|
|
|
(77,413
|
)
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in) financing activities
|
|
|
(44,877
|
)
|
|
|
10,815
|
|
|
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash and cash equivalents
|
|
|
(15,369
|
)
|
|
|
1,653
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Increase in cash and cash equivalents
|
|
$
|
76,157
|
|
|
$
|
63,198
|
|
|
|
|
|
|
|
|
|
|
Net cash provided from operating activities was $163.1 million and $128.1 million in the
2005 Period and 2004 Period, respectively. The primary sources of net cash provided from
operating activities were net income, the adding back of depreciation and amortization, the
reduction of accounts receivable, and the increase in deferred revenue. Included in the net
income for the 2004 Period was $17.1 million in proceeds for the Perkin-Elmer litigation
judgment. Depreciation and amortization increased in the 2005 Period primarily from the effect
of the purchase of a new building in Milford, Massachusetts. The change in accounts receivable
in 2005 Period compared to the 2004 Period is primarily attributable to the timing of payments
made by customers which resulted in the days-sales-outstanding (DSO) decreasing to 73 days at
July 2, 2005 from 78 days at July 3, 2004. Currency translation decreased DSO by approximately
one day in the 2005 Period.
21
The changes in accounts payable and other current liabilities in the 2005 Period versus the
2004 Period are primarily due to higher incentive compensation payments made in the 2005 Period
based on 2004 results. The change in accounts payable and other current liabilities was also
impacted by the lower accounts payable balance, which was offset by increases in tax liabilities
resulting from the timing of estimated tax payments. The increases in deferred revenue and
customer advances are from invoicing for annual service contracts at the beginning of each fiscal
year and overall growth in the service business. The reduction in the change in accrued litigation
is primarily a result of an $18.1 million payment made in the 2004 Period regarding the Applera
litigation, offset by a $7.8 million provision, also made in the 2004 Period, related to the
Hewlett-Packard litigation.
Net cash used in investing activities totaled $26.7 million and $77.4 million in the 2005
Period and 2004 Period, respectively. Additions to fixed assets and intangible assets were $26.7
million in the 2005 Period and $35.9 million in the 2004 Period. Included in the 2004 Period was a
250 thousand square foot building purchase adjacent to the Companys headquarters for $18.1
million. The remaining increase is primarily a result of recent expansion efforts related to
multiple facilities to accommodate future growth. Cash paid for business acquisitions, net of cash
acquired were zero and $41.5 million in the 2005 Period and the 2004 Period, respectively.
With respect to cash provided by (used in) financing activities, the Company repurchased 4.2
million shares of its common stock for an aggregate of $175.0 million during the 2004 Period. On
October 25, 2004, the Companys Board of Directors authorized the Company to repurchase up to an
additional $500.0 million in outstanding common shares over a two-year period. The Company
believes that the share repurchase program benefits shareholders by increasing earnings per share
through reducing the outstanding shares and that the Company is likely to have adequate financial
flexibility to fund these share repurchases given current cash and debt levels. As of July 2,
2005, 6.8 million shares have been purchased under this plan for an aggregate of $304.9 million of
which $248.6 million was paid in the 2005 Period. The Company received $11.2 million of proceeds
from other financing activities in the 2005 Period from the exercise of stock options and the
purchase of shares pursuant to its employee stock purchase plans. The Company also made net
payments of $8.2 million on derivative contracts. The Company received $21.6 million of proceeds
from other financing activities in the 2004 Period from the exercise of stock options and the purchase of
shares pursuant to the employee stock purchase plans.
The Company had net borrowings at the end of the 2005 Period of $657.4 million, primarily
relating to borrowings in the U.S. under the Companys syndicated committed Credit Agreement (the
Credit Agreement), dated December 2004. The Credit Agreement provides a $250.0 million term loan
facility and a $450.0 million revolving facility which includes both a letter of credit and a
swingline subfacility. The Company increased its net borrowings of bank debt by $200.8 million and
$163.2 million during the 2005 Period and 2004 Period, respectively.
The Company believes that the cash and cash equivalent balance of $615.2 million at the end of
the 2005 Period and expected cash flow from operating activities together with borrowings available
from the Credit Agreement and other short-term domestic facilities will be sufficient to fund
working capital, capital spending requirements, acquisitions, authorized share repurchase amounts
and any adverse final determination of ongoing litigation for at least the next twelve months.
Management believes, as of the date of this report, that its financial position along with expected
future cash flows from earnings based on historical trends and the ability to raise funds from a
number of financing alternatives and external sources will be sufficient to meet operating and
investing needs for the foreseeable future.
Contractual Obligations and Commercial Commitments:
A summary of the Companys contractual obligations and commercial commitments is included in the
Companys annual report on Form 10-K for the year ended December 31, 2004. The Company reviewed
its contractual obligations and commercial commitments as of July 2, 2005, and determined that
there were no significant changes.
From time to time, the Company and its subsidiaries are involved in various litigation
matters arising in the ordinary course of business. The Company believes that any outcome of
such matters will not be material to its financial position or results of operations.
During fiscal year 2005, the Company expects to contribute approximately $6.5 million to the
Companys retirement plans in the third quarter of 2005. No payments were made in the 2005
Period.
The Company also anticipates paying a majority of the tax liability related to the recently
adopted $500.0 million dividend repatriation under AJCA in the fourth quarter of 2005 and the
first quarter of 2006. It is estimated that this tax liability will be between $22.0 million and
$28.0 million.
22
The Company is not aware of any undisclosed risks and uncertainties, including but not
limited to product technical obsolescence, regulatory compliance, protection of intellectual
property rights, changes in pharmaceutical industry spending, competitive advantages, current and
pending litigation, and changes in foreign exchanges rates, that are reasonably likely to occur
and could materially and negatively affect the Companys existing cash balance or its ability to
borrow funds from its credit facility. The Company also believes there are no provisions in the
Credit Agreement, its real estate leases, and supplier and collaborative agreements that would
accelerate payments, require additional collateral or impair its ability to continue to enter
into critical transactions. The Company has not paid any dividends and does not plan to pay any
dividends in the foreseeable future.
Critical Accounting Policies and Estimates
In the Companys annual report on Form 10-K for the year ended December 31, 2004, the Companys
most critical accounting policies and estimates upon which its financial status depends, were
identified as those relating to revenue recognition, loss provisions on accounts receivable and
inventory, valuation of equity investments, long-lived assets, intangible assets and goodwill,
warranty, income taxes and litigation. The Company reviewed its policies and determined that
those policies remain the Companys most critical accounting policies for the 2005 Period. The
Company did not make any changes in those policies during the 2005 Period.
Forward-Looking Information
Safe Harbor Statement under Private Securities Litigation Reform Act of 1995
The statements included in this quarterly report on Form 10-Q may contain forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, (the Exchange Act) regarding
future results and events, including statements regarding expected financial results, future
growth and customer demand and uncertainty relating to patent litigation that involve a number of risks and
uncertainties. For this purpose, any statements contained herein that are not statements of
historical fact may be deemed forward-looking statements. Without limiting the foregoing, the
words, believes, anticipates, plans, expects, intends, appears, estimates,
projects, and similar expressions are intended to identify forward-looking statements. The
Companys actual future results may differ significantly from the results discussed in the
forward-looking statements within this quarterly report for a variety of reasons, including and
without limitation, fluctuations in capital expenditures by our customers, in particular large
pharmaceutical companies, introduction of competing products, such as improved research-grade
mass spectrometers, by other companies, pressures on prices from competitors and/or customers,
regulatory obstacles to new product introductions, lack of acceptance of new products, other
changes in the demands of the Companys healthcare and pharmaceutical company customers, changes
in distribution of the Companys products, changes in the healthcare market and the
pharmaceutical industry, loss of market share through competition, potential product liability or
other claims against the Company as a result of the use of its products, risks associated with
lawsuits and other legal actions particularly involving claims for infringement of patents and
other intellectual property rights, and foreign exchange rate fluctuations potentially adversely
affecting translation of the Companys future non-U.S. operating results . Such factors
and others are discussed more fully in the section entitled Risk Factors of the Companys
annual report on Form 10-K for the year ended December 31, 2004, as filed with the Securities and
Exchange Commission (the SEC), which Risk Factors discussion is incorporated by reference in
this quarterly report. The forward-looking statements included in this quarterly report represent
the Companys estimates or views as of the date of this quarterly report and should not be relied
upon as representing the Companys estimates or views as of any date subsequent to the date of
this quarterly report. The Company specifically disclaims any obligation to update these
forward-looking statements in the future.
Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
There have been no material changes in the Companys market risk during the six months ended July
2, 2005. For additional information regarding the Companys market risk as of December 31, 2004,
refer to Item 7a of Part I of the Companys Form 10-K for the year ended December 31, 2004, as
filed with the SEC.
23
Item 4. CONTROLS AND PROCEDURES
(a) Evaluation of Disclosure Controls and Procedures
The Companys management, with the participation of the Companys chief executive officer and
chief financial officer, evaluated the effectiveness of the Companys disclosure controls and
procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of
1934, as amended (the Exchange Act)) as of the end of the period covered by this quarterly
report on Form 10-Q. Based on this evaluation, the Companys chief executive officer and chief
financial officer concluded that the Companys disclosure controls and procedures were (1)
designed to ensure that material information relating to the Company, including its consolidated
subsidiaries, is made known to the Companys chief executive officer and chief financial officer
by others within those entities, particularly during the period in which this report was being
prepared, and (2) effective, in that they provide reasonable assurance that information required
to be disclosed by the Company in the reports that it files or submits under the Exchange Act is
recorded, processed, summarized and reported within the time periods specified in the SECs rules
and forms.
(b) Changes in Internal Controls
No change in the Companys internal control over financial reporting (as defined in Rules
13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the three months ended July 2,
2005 that has materially affected, or is reasonably likely to materially affect, the Companys
internal control over financial reporting.
Part II: OTHER INFORMATION
Item 1. Legal Proceedings
There have been no material changes in the Companys legal proceedings during the six months
ended July 2, 2005. For additional information, refer to Item 3 of Part I of the Companys Form
10-K for the year ended December 31, 2004, as filed with the SEC.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
The following table provides information about purchases by the Company during the three months
ended July 2, 2005 of equity securities registered by the Company pursuant to the Exchange Act
(in thousands, except per share data):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(c) Total Number
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
of Shares
|
|
|
(d) Maximum Dollar
|
|
|
|
(a) Total
|
|
|
|
|
|
|
Purchased as
|
|
|
Value of Shares that
|
|
|
|
Number of
|
|
|
(b) Average
|
|
|
Part of Publicly
|
|
|
May Yet Be
|
|
|
|
Shares
|
|
|
Price Paid
|
|
|
Announced
|
|
|
Purchased Under the
|
|
Period
|
|
Purchased (1)
|
|
|
per Share
|
|
|
Programs (2)
|
|
|
Programs (3)
|
|
|
April 3 to 30, 2005
|
|
|
350
|
|
|
$
|
38.95
|
|
|
|
350
|
|
|
$
|
281,588
|
|
May 1 to 28, 2005
|
|
|
1,475
|
|
|
|
39.77
|
|
|
|
1,475
|
|
|
|
222,927
|
|
May 29 to July 2,
2005
|
|
|
720
|
|
|
|
38.66
|
|
|
|
720
|
|
|
|
195,093
|
|
|
|
|
Total
|
|
|
2,545
|
|
|
$
|
39.34
|
|
|
|
2,545
|
|
|
$
|
195,093
|
|
|
|
|
|
|
|
(1)
|
|
To date the Company has purchased an aggregate of 6.8 million shares of its common stock in
open market transactions pursuant to a repurchase program (the Program) authorized on
October 25, 2004.
|
|
(2)
|
|
The Companys Board of Directors approved the repurchase by the Company of up to $500.0
million of its outstanding common stock pursuant to the Program. The expiration date of the
Program is October 25, 2006.
|
|
(3)
|
|
The approximate dollar value of shares that may yet be purchased under the Program was
$195.1 million at July 2, 2005.
|
Item 3. Defaults Upon Senior Securities
Not Applicable
24
Item 4. Submission of Matters to a Vote of Security Holders
The Waters Corporation annual meeting of stockholders was held on May 4, 2005, at which the
following matters were submitted to a vote of security holders: 1) the election of directors of
the Company; and 2) ratification of the selection of PricewaterhouseCoopers LLP as the Companys
independent registered public accounting firm for the fiscal year ending December 31, 2005. As
of March 15, 2005, the record date for that meeting, there were 117,741,488 shares of Waters
Corporation common stock entitled to vote at the meeting. At that meeting, the holders of
102,568,783 shares were represented in person or by proxy, constituting a quorum. At that
meeting, the vote with respect to the matters proposed to the stockholders was as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Matter
|
|
For
|
|
Withheld
|
|
Against
|
|
Abstain
|
Election
of Directors:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For Joshua Bekenstein
|
|
|
98,104,369
|
|
|
|
4,464,414
|
|
|
|
|
|
|
|
|
|
For Michael J. Berendt, Ph.D.
|
|
|
100,411,640
|
|
|
|
2,157,143
|
|
|
|
|
|
|
|
|
|
For Douglas A. Berthiaume
|
|
|
97,837,255
|
|
|
|
4,731,528
|
|
|
|
|
|
|
|
|
|
For Edward Conard
|
|
|
93,114,246
|
|
|
|
9,454,537
|
|
|
|
|
|
|
|
|
|
For Laurie H. Glimcher, M.D.
|
|
|
100,407,736
|
|
|
|
2,161,047
|
|
|
|
|
|
|
|
|
|
For William J. Miller
|
|
|
98,224,637
|
|
|
|
4,344,146
|
|
|
|
|
|
|
|
|
|
For Thomas P. Salice
|
|
|
93,370,952
|
|
|
|
9,197,831
|
|
|
|
|
|
|
|
|
|
Ratification of the selection of PricewaterhouseCoopers LLP as the Companys independent
registered public accounting firm for the fiscal year ending December 31, 2005:
|
|
|
|
|
For
|
|
|
100,927,093
|
|
Against
|
|
|
805,283
|
|
Abstain
|
|
|
836,407
|
|
No-Vote
|
|
|
|
|
Item 5. Other Information
Not Applicable
Item 6. Exhibits
|
|
|
Exhibit 10.38
|
|
Second Amendment to the Waters Corporation 2003 Equity Incentive Plan.
|
|
|
|
Exhibit 31.1
|
|
Chief Executive Officer Certification Pursuant to 18 U.S.C. Section 1350, as Adopted
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
Exhibit 31.2
|
|
Chief Financial Officer Certification Pursuant to 18 U.S.C. Section 1350, as Adopted
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
Exhibit 32.1
|
|
Chief Executive Officer Certification Pursuant to 18 U.S.C. Section 1350, as Adopted
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
Exhibit 32.2
|
|
Chief Financial Officer Certification Pursuant to 18 U.S.C. Section 1350, as Adopted
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
25
WATERS CORPORATION AND SUBSIDIARIES
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
Date: August 5, 2005
|
|
Waters Corporation
|
|
|
|
|
|
/s/ John Ornell
|
|
|
|
|
|
John Ornell
|
|
|
Authorized Officer, Vice President, Finance and
|
|
|
Administration and Chief Financial Officer
|
26